Homocysteine and lipoprotein (a) correlation in ischemic stroke patients

Journal of the Neurological Sciences

Volumn 281, Issue 1-2, 2009, Pages 64-68

  Dhamija, Rajinder K ^a   Gaba, P ^a   Arora, S ^a   Kaintura, A ^a   Kumar, M ^a   Bhattacharjee, J ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Correlation; Homocysteine; Ischemic stroke; Lipoprotein (a); Risk factors; Smoking

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; VENOUS BLOOD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN ISCHEMIA; CHOLESTEROL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; ODDS RATIO; SMOKING; STROKE; YOUNG ADULT;

EID: 67349243473     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.02.341     Document Type: Article

References (42)

1. Milionis H.J., Liberopoulos E., Goudevenos J., Bairaktari E.T., Seferiadis K., and Elisaf M.S. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 99 2 (Mar 18 2005) 269-275
2. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease study. Lancet 349 (1997) 1498-1504
3. Dalal P.M. Burden of stroke - Indian perspective. JAPI 52 (Sept. 2004) 695-696
4. Sacco R.L. Newer risk factors for stroke. Neurology 57 5 Suppl 2 (2001) S31-34
5. Torbus-Lisiecka B., Bukowska H., Jastrzebska M., Chelstowski K., Honczarenko K., and Naruszewicz M. Lp(a), homocysteine and a family history of early ischemic cerebral stroke. Nutr Metab Cardiovasc Dis 11 Suppl 5 (Oct 2001) 52-59
6. Mc Cully K.S. Vascular pathology of hyperhomocysteinemia: implication for pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
7. Lentz S.R., Sobey C.G., Piegors D.J., Bhopatkar M.Y., Faraci F.M., Malinow M.R., et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98 (1996) 24-29
8. Stamler J.S., Osborne J.A., Jaraki O., Rabbani L.E., Mullins M., Singel D., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91 (1993) 308-318
9. Tawakol A., Omland T., Gerhard M., Wu J.T., and Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 95 (1997) 1119-1121
10. Snehalata C., Ramachandran A., Satyavani K., Sivasankari S., Satyamurti I., and Vishwanathan V. Plasma homocysteine concentration and coronary artery disease in Asian Indians. JAPI 50 (2002) 1229-1231
11. Deepa R., Velmurugan K., Saravanan G., Karkuzhali V., Dwarkanath V., and Mohan V. Absence of association between serum homocysteine levels and coronary artery disease in south Indian males. Indian Heart J 53 (2001) 44-47
12. Sobczak A., Wardas W., Zielinska-Danch W., and Pawlicki K. The influence of smoking on plasma homocysteine and cysteine levels in passive and active smokers. Clin Chem Lab Med 42 4 (April 2004) 408-414
13. Panagiotakos D.B., Pitsavos C., Chrysohoou C., Skoumas J., Masoura C., Toutouzas P., et al. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med 116 3 (Feb 1 2004) 145-150
14. Foody J.A.M., Milberg J.A., Robinson K., Pearce G.L., Jacobsen D.W., and Sprecher D.L. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 20 2 (2000) 493-499
15. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
16. Bhargava S., Parakh R., and Srivastava L.M. Studies on homocysteine demonstrating its significance as a possible tool for differential diagnosis in occlusive vascular Disease. Ind J Clin Biochem 19 1 (2004) 76-78
17. Farmer J.A., and Gotto Jr. A.M. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E. (Ed). Heart Disease: A Textbook of Cardiovascular Medicine. (5th ed.) (1997), WB Saunders, Philadelphia 1126-1160
18. Uno M., Kitazato K.T., Nishi K., Itabe H., and Nagahiro S. Raised plasma oxidized LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 74 (2003) 312-316
19. Kelly D.K., Wolf P.A., Cupples L.A., Beiser A.S., and Myers R.H. Familial aggregation of stroke: the Framingham study. Stroke 24 (1993) 1366-1371
20. Reis R.P., Azinheira J., Reis H.P., Pereira M., Baptista A., Crepo M., et al. Homocysteinemia as a risk factor for cerebrovascular disorders. The role of age and homocysteine levels. Acta Med Port 9 1 (1996) 15-20
21. Eikelboom J.W., Hankey G.J., Anand S.S., Lofthouse E., Staples N., and Baker R.I. Association between high homocyst(e)ine and ischemic stroke due to large- and small- artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31 (2000) 1069
22. Bushnell C.D., and Goldstein L.B. Homocysteine testing in patients with acute ischemic stroke. Neurology 59 10 (2002) 1541-1546
23. Fallon U.B., Elwood P., Ben-Shlomo Y., Ubbink J.B., Greenwood R., and Smith G.D. Homocysteine and ischemic stroke in men: the Caerphilly study. J Epidemiol Community Health 55 2 (Feb 2001) 91-96
24. Moller J., Nielsen G.M., Tvedegaard K.C., Andersen N.T., and Jorgensen P.E. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 60 6 (Oct 2000) 491-499
25. Laraqui A., Bennouar N., Meggouh F., Allami A., Kadiri N.E., Benkouka F., et al. Homocysteine, lipoprotein(a): risk factors for coronary heart disease. Ann Biol Clin (Paris) 60 5 (Sep-Oct 2002) 549-557
26. Reis R.P., Azinheira J., Reis H.P., Pina J.E., Correia J.M., and Luis A.S. Influence of smoking on homocysteinemia at baseline and after methionine load. Rev Port Cardiol 19 4 (2000) 71-74
27. Scanu A.M., and Fless G.M. Lipoprotein(a) heterogeneity and biological relevance. J Clin Invest 85 (1990) 1709-1715
28. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci 61 (1997) 1205-1215
29. Ali A., Mehra M.R., and Lavie C.J. Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Am J Cardiol 82 (1998) 1543-1545
30. Lavie C.J., Milani R.V., and O'Keefe J.H. Update on new coronary risk factors (editorial). Chest 110 (1996) 583-584
31. Vinukonda G. Plasma homocysteine and methylenetetrahydrofolate reductase gene polymorphism in human health and disease: an update. Int J Hum Genet 8 1-2 (2008) 171-179
32. Angeline T., Jeyaraj N., Granito S., and Tsongalis G.J. Prevalence of MTHFR gene polymorphisms (C677T and A1298C) among Tamilans. Exp Mol Pathol 77 (2004) 85-88
33. Kalita J., Srivastva R., Bansal V., Agarwal S., and Misra U.K. Methylene tertahydrofolate reductase gene polymorphism in Indian stroke patients. Neurol India 54 (2006) 260-263
34. Jurgens G., and Koltringer P. Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries. Chem Phys Lipids 67/68 (1994) 429-434
35. Ohtahara A., Hisatome I., Yamamoto Y., Furuse M., Sonoyama K., Furuse Y., et al. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. J Hypertens 19 3 (2001) 575-582 Suppl
36. Harpel P.C., Chang V.T., and Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS (1992) 10193-10197
37. Howard V.J., Sides E.G., Newman G.C., Cohen S.N., Howard G., Malinow M.R., et al. for the stability of plasma homocystein in acute stroke patients (SHASP) study investigators. Changes in plasma homocystein in acute phase after stroke. Stroke 33 (2002) 473-478
38. Chandalia M., Abate N., Cabo- Chan Jr. A.V., Devaraj S., Jialal I., and Grundy S.M. Hyperhomocysteinemia in Asian Indians living in the United States. J Clin Endocrinol Metab 88 3 (2003) 1089-1095
39. Perry I.J. Homocysteine and risk of stroke. J Cardiovasc Risk 6 4 (1999) 235-240
40. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
41. Ebbing M., Bleie Ø., Ueland P.M., Nordrehaug J.E., Nilsen D.W., Vollset S.E., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300 7 (2008) 795-804
42. The VITATOPS Trial Study Group. VITATOPS, the VITAmins TO Prevent Stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke. Int J Stroke 2 2 (2007) 144-150